AOM Infusion Joins Limited Distribution Network for QIVIGY® Immune Globulin Therapy
AOM Infusion, a leading specialty infusion pharmacy and care provider in the United States, has announced that it has been selected to join the limited distribution network for QIVIGY, a newly introduced 10% immune globulin therapy developed by Kedrion Biopharma. The therapy is indicated for the treatment of adults living with Primary Humoral Immunodeficiency (PI), a condition in which the body’s immune system does not produce enough antibodies to effectively fight infections.
The addition of QIVIGY to AOM Infusion’s therapy offerings expands the organization’s growing immune globulin portfolio and further strengthens its mission of providing advanced treatment options for patients with complex immune disorders. The announcement also follows AOM Infusion’s recent collaboration with Kedrion Biopharma to distribute another immune globulin therapy, YIMMUGO, which is also used to treat patients with primary immunodeficiency conditions.
Expanding Access to Innovative Immune Therapies
QIVIGY is a ready-to-use, sterile, and non-pyrogenic liquid solution of human immune globulin (IgG) designed for intravenous (IV) administration. The therapy delivers a broad spectrum of antibodies that help protect patients against a variety of bacterial and viral infections. For individuals diagnosed with primary immunodeficiency disorders—conditions that weaken the body’s natural ability to fight infections—immune globulin therapies play a critical role in maintaining immune function and preventing serious complications.
By adding QIVIGY to its infusion therapy portfolio, AOM Infusion aims to provide healthcare providers and patients with another reliable treatment option for managing primary immunodeficiency. The therapy’s ready-to-use formulation also helps streamline infusion preparation and administration, supporting efficient and safe treatment delivery.
Kedrion Biopharma selected AOM Infusion as one of its specialty pharmacy distribution partners due to the company’s extensive expertise in immune globulin therapies, its nationwide reach, and its patient-centered clinical model. With more than three decades of experience delivering infusion treatments, AOM Infusion has developed a strong reputation for supporting patients with chronic and rare conditions through comprehensive care programs.
Commitment to Clinical Excellence
AOM Infusion has been widely recognized for its commitment to high standards of care, particularly in the area of immune globulin therapy. The organization was among the first specialty infusion providers in the United States to earn the Distinction in Immunoglobulin Therapy from the Accreditation Commission for Health Care (ACHC) and the Immunoglobulin National Society (IgNS). This distinction reflects excellence in clinical protocols, patient safety practices, and outcomes-focused treatment delivery.
The recognition highlights AOM’s dedication to ensuring patients receive the safest and most effective care possible. It also demonstrates the organization’s focus on supporting physicians with reliable treatment pathways and specialized expertise in immunoglobulin therapies.
Strengthening a Strategic Partnership
Leaders from Kedrion Biopharma emphasized that the partnership with AOM Infusion will help expand patient access to the newly launched therapy.
“We’re proud to make QIVIGY available nationwide, offering a reliable new option for patients in need of IVIG therapy,” said Bob Rossilli, Chief Commercial Officer of Kedrion. “Through our long-standing relationship with AOM Infusion, we aim to reach patients where they are and ensure access to the therapies they need most. By combining our expertise and resources, we can bring QIVIGY to more communities and help support patients and families.”
AOM Infusion leaders also highlighted the importance of collaboration in expanding treatment access for patients with complex immune conditions.
“This partnership with Kedrion reflects our shared commitment to improving access to life-enhancing therapies for patients with complex immune disorders,” said Karmen Stowe, Vice President of Trade Relations and Supply Chain at AOM Infusion. “By expanding our immunoglobulin portfolio with QIVIGY, we are strengthening our ability to support providers with reliable therapy options while helping patients receive high-quality infusion care that best supports their lives.”
Supporting Patients with Complex Conditions
Primary immunodeficiency disorders affect thousands of individuals and often require long-term management through immunoglobulin replacement therapy. Patients living with these conditions may experience frequent infections, fatigue, and other complications due to the body’s inability to produce sufficient antibodies.
Immune globulin treatments such as QIVIGY help replace missing antibodies, supporting the immune system and reducing the risk of infections. By making these therapies more accessible through specialized infusion pharmacies, healthcare providers can ensure patients receive consistent and personalized care.
About AOM Infusion
AOM Infusion is a nationally licensed specialty infusion pharmacy with more than 30 years of experience delivering advanced infusion therapies for patients with chronic and complex medical conditions. The company provides treatment solutions across more than 80 disease states and continues to expand its therapy programs nationwide.
The organization has been recognized for both clinical excellence and business growth, including being named to the Inc. 5000 list of fastest-growing private companies. Through ongoing investment in innovative care platforms, clinical expertise, and patient-centered services, AOM Infusion continues to enhance access to high-quality infusion care across the United States.
With the addition of QIVIGY to its portfolio and its ongoing partnership with Kedrion Biopharma, AOM Infusion aims to further strengthen its ability to support patients, healthcare providers, and families navigating the challenges of immune system disorders.
Source link :https://www.businesswire.com/
